MCID: LMB062
MIFTS: 50

Limb Ischemia

Categories: Cardiovascular diseases

Aliases & Classifications for Limb Ischemia

MalaCards integrated aliases for Limb Ischemia:

Name: Limb Ischemia 12 15 72

Classifications:



External Ids:

Disease Ontology 12 DOID:0050852
UMLS 72 C2945695

Summaries for Limb Ischemia

Disease Ontology : 12 An ischemia that is characterized by low blood supply to tissues in the limb due to interruption in the arterial blood supply.

MalaCards based summary : Limb Ischemia is related to end stage renal failure and peripheral artery disease. An important gene associated with Limb Ischemia is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Dexamethasone and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include endothelial, bone and bone marrow, and related phenotypes are cardiovascular system and hematopoietic system

Related Diseases for Limb Ischemia

Diseases related to Limb Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 388)
# Related Disease Score Top Affiliating Genes
1 end stage renal failure 31.0 TNF IL6 ACE
2 peripheral artery disease 30.9 VEGFA NOS3 IL6 CCL2 ACE
3 cardiogenic shock 30.8 TNF PLAT IL6
4 intermittent claudication 30.8 VWF VEGFA IL6 ACE
5 endocarditis 30.6 TNF PLAT IL6
6 purpura 30.5 VWF TNF IL6
7 vasculitis 30.5 VWF TNF SELE CCL2
8 atherosclerosis susceptibility 30.3 TNF SELE NOS3 IL6 CCL2
9 proteasome-associated autoinflammatory syndrome 1 30.3 TNF SELE IL6 CCL2
10 varicose veins 30.2 VWF VEGFA HIF1A
11 antiphospholipid syndrome 30.1 VWF SELE PLAT
12 peripheral vascular disease 30.0 VWF VEGFA SELE PLAT IL6 ACE
13 ischemia 30.0 VEGFA PLAT NOS3 HIF1A EDN1 CXCL12
14 pulmonary edema 29.9 TNF NOS3 EDN1 ACE
15 leukostasis 29.9 VEGFA SELE KDR
16 lung disease 29.8 TNF IL6 EDN1 CCL2
17 kawasaki disease 29.8 TNF SELE IL6 CCL2
18 systemic scleroderma 29.8 SELE EDN1 ACE
19 aortic coarctation 29.7 NOS3 EDN1 ACE
20 arteriosclerosis 29.7 SELE IL6 HGF EDN1 CCL2 ACE
21 connective tissue disease 29.7 TNF IL6 EDN1 ACE
22 kidney disease 29.6 NOS3 IL6 EDN1 CCL2 ACE
23 renovascular hypertension 29.6 NOS3 EDN1 ACE
24 central nervous system disease 29.6 TNF PLAT IL6 CCL2
25 coronary artery anomaly 29.5 PLAT NOS3 EDN1 ACE
26 coronary heart disease 1 29.5 PLAT NOS3 IL6 ACE
27 carotid artery disease 29.5 SELE CCL2 ACE
28 diabetic angiopathy 29.5 VWF SELE EDN1 CCL2
29 hemangioma 29.3 VEGFA TEK KDR HIF1A FGF2
30 acute myocardial infarction 29.2 VWF PLAT EDN1 ACE
31 diabetes mellitus 29.1 VEGFA TNF NOS3 IL6 EDN1 ACE
32 cerebrovascular disease 29.1 VWF TNF SELE PLAT IL6 ACE
33 intermediate coronary syndrome 29.1 VWF PLAT IL6 ACE
34 sleep apnea 29.1 TNF NOS3 IL6 EDN1 ACE
35 myeloma, multiple 29.0 VEGFA TNF IL6 HGF FGF2 CXCL12
36 angina pectoris 28.9 PLAT NOS3 IL6 EDN1 ACE
37 dilated cardiomyopathy 28.9 TNF NOS3 IL6 EDN1 ACE
38 microvascular complications of diabetes 1 28.8 VEGFA HGF FGF2 EDN1 CXCL12 CCL2
39 systemic lupus erythematosus 28.5 VWF TNF SELE IL6 CCL2 ACE
40 nervous system disease 28.5 VEGFA TNF PLAT IL6 CCL2 ACE
41 pulmonary hypertension 28.4 VWF PLAT NOS3 HIF1A EDN1 ACE
42 microvascular complications of diabetes 5 27.7 VEGFA TEK PGF NOS3 KDR FGF2
43 vascular disease 27.6 VWF VEGFA TNF SELE PLAT NOS3
44 arteries, anomalies of 26.6 VWF VEGFA TNF SELE PLAT PGF
45 myocardial infarction 25.4 VWF VEGFA TNF PLAT PGF NOS3
46 scorpion envenomation 10.7 TNF IL6
47 intravascular papillary endothelial hyperplasia 10.7 VEGFA HIF1A
48 hemifacial spasm 10.6 VEGFA NOS3
49 angioimmunoblastic lymphadenopathy with dysproteinemia 10.6 TNF IL6
50 autoimmune myocarditis 10.6 TNF IL6

Graphical network of the top 20 diseases related to Limb Ischemia:



Diseases related to Limb Ischemia

Symptoms & Phenotypes for Limb Ischemia

MGI Mouse Phenotypes related to Limb Ischemia:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.49 ACE CXCL12 EDN1 FGF2 HGF HIF1A
2 hematopoietic system MP:0005397 10.38 ACE CXCL12 FGF2 HGF HIF1A IL6
3 homeostasis/metabolism MP:0005376 10.37 ACE EDN1 FGF2 HIF1A IL6 KDR
4 cellular MP:0005384 10.36 CXCL12 FGF2 HGF HIF1A IL6 KDR
5 growth/size/body region MP:0005378 10.36 ACE EDN1 HGF HIF1A IL6 KDR
6 mortality/aging MP:0010768 10.33 ACE CXCL12 EDN1 FGF2 HGF HIF1A
7 immune system MP:0005387 10.32 ACE CCL2 CXCL12 HIF1A IL6 KDR
8 behavior/neurological MP:0005386 10.3 ACE FGF2 HIF1A IL6 KDR NOS3
9 digestive/alimentary MP:0005381 10.18 EDN1 HIF1A IL6 NOS3 PLAT TNF
10 liver/biliary system MP:0005370 10.18 ACE CXCL12 HGF HIF1A IL6 KDR
11 embryo MP:0005380 10.17 EDN1 HGF HIF1A KDR PGF TEK
12 muscle MP:0005369 10.17 CXCL12 EDN1 FGF2 HIF1A IL6 KDR
13 endocrine/exocrine gland MP:0005379 10.16 ACE EDN1 HIF1A IL6 NOS3 PLAT
14 nervous system MP:0003631 10.15 CXCL12 EDN1 FGF2 HIF1A IL6 KDR
15 integument MP:0010771 10.1 HIF1A IL6 KDR PGF PLAT SELE
16 neoplasm MP:0002006 9.95 ACE FGF2 HIF1A IL6 PGF TNF
17 normal MP:0002873 9.92 CXCL12 EDN1 HIF1A KDR NOS3 SELE
18 reproductive system MP:0005389 9.86 ACE CXCL12 FGF2 IL6 NOS3 PLAT
19 respiratory system MP:0005388 9.81 HIF1A IL6 KDR NOS3 PGF PLAT
20 skeleton MP:0005390 9.61 EDN1 FGF2 HIF1A IL6 KDR NOS3
21 vision/eye MP:0005391 9.36 FGF2 HIF1A IL6 KDR NOS3 PGF

Drugs & Therapeutics for Limb Ischemia

Drugs for Limb Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 219)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
3
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723 149351
4
Menthol Approved Phase 4 2216-51-5 16666
5
Simvastatin Approved Phase 4 79902-63-9 54454
6
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
7
Esmolol Approved Phase 4 103598-03-4, 81147-92-4 59768
8
carbamide peroxide Approved Phase 4 124-43-6
9
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
10
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
11
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
12
Ticagrelor Approved Phase 4 274693-27-5 9871419
13
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
14
tannic acid Approved Phase 4 1401-55-4
15
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
16
Metformin Approved Phase 4 657-24-9 4091 14219
17
Zinc Approved, Investigational Phase 4 7440-66-6 32051
18
Adenosine Approved, Investigational Phase 4 58-61-7 60961
19
Insulin glargine Approved Phase 4 160337-95-1
20
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
21
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
22
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
23 Blood Substitutes Phase 4
24 Gastrointestinal Agents Phase 4
25 Dexamethasone 21-phosphate Phase 4
26 Antiemetics Phase 4
27 glucocorticoids Phase 4
28 Antineoplastic Agents, Hormonal Phase 4
29 Hormone Antagonists Phase 4
30 BB 1101 Phase 4
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
32 Vitamins Phase 4
33 Dermatologic Agents Phase 4
34 Antipruritics Phase 4
35 Micronutrients Phase 4
36 Nutrients Phase 4
37 Trace Elements Phase 4
38 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
39 arginine Phase 4
40 Vitamin B9 Phase 4
41 Folate Phase 4
42 Vitamin B Complex Phase 4
43 Vitamin B3 Phase 4
44 Nicotinic Acids Phase 4
45 Hypolipidemic Agents Phase 4
46 Lipid Regulating Agents Phase 4
47 Antimetabolites Phase 4
48 Anticholesteremic Agents Phase 4
49 Adrenergic beta-1 Receptor Antagonists Phase 4
50 Adrenergic beta-Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 466)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia Unknown status NCT02563535 Phase 4
2 Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part I) Unknown status NCT01171703 Phase 4
3 DCLI-II:Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part II) Unknown status NCT01173094 Phase 4
4 Drug Eluting Balloon in peripherAl inTErvention for Below-The-Knee Arteries With Freeway and Lutonix Unknown status NCT02279784 Phase 4
5 The Prism Trial: A Retrospective Case Review of Technical Success Using the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery Unknown status NCT02085551 Phase 4
6 The Study to Compare the Treatment of Stent and Prothesis Bypass in SFA Occlusions Unknown status NCT01147419 Phase 4
7 The Effect of Far Infrared (FIR) Therapy on Access Flow of Arteriovenous (AV) Fistula, Echocardiographic Parameters and Endothelial Function in Patients With End Stage Renal Disease Unknown status NCT01138254 Phase 4
8 Drug Eluting Balloon in peripherAl inTErvention For Below The Knee Angioplasty Evaluation: the DEBATE-BTK Study Completed NCT01558505 Phase 4
9 CLIMB Prospective Multicenter Registry Evaluating the Use of the PolarCath Peripheral Dilatation System (Boston Scientific) in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia (Rutherford 4 and 5). Completed NCT00459888 Phase 4
10 EXPAND Study - Self Expanding Nitinol Stent Versus PTA With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication. A Prospective, Multi-center, Randomized Clinical Trail With Follow-up Investigations at 1, 3, 6, and 12 Months. Completed NCT00906022 Phase 4
11 International Postmarketing Surveillance Study of Pl-VEGF165 Safety and Efficacy in 210 Patients With Peripheral Arterial Disease Completed NCT02369809 Phase 4 Neovasculgen®
12 NanoCross BTK, a Prospective, Non-randomized, Multicenter, Controlled Trial Evaluating the Performance of the NanoCrossTM .014 Balloon Catheter in Infrapopliteal Lesions Completed NCT01783600 Phase 4
13 Physician Initiated Multi-center Belgian-Italian-Dutch Trial Investigating Abbott Vascular Iliac Stents in the Treatment of TASC A, B, C & D Iliac Lesions Completed NCT00764777 Phase 4
14 Physician Initiated Trial Investigating the Efficacy of the Implant of EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions Completed NCT00637741 Phase 4
15 Multinational, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Efficacy and Safety of Prostaglandin E1 in Subjects With Critical Limb Ischemia (Fontaine Stage IV) Completed NCT00596752 Phase 4 Alprostadil
16 Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization Completed NCT01983449 Phase 4 Dexamethasone Sodium Phosphate Injection, USP
17 Effect of Combined Remote Ischemic Preconditioning and Postconditioning on Acute Pulmonary Injury in Patients Undergoing Valvular Heart Surgery Completed NCT01427621 Phase 4
18 Balloon Angioplasty Versus Stenting With Nitinol Stents in the Superficial Femoral Artery Completed NCT00281060 Phase 4
19 Protective Effects of L-arginine During Reperfusion by Femoropopliteal Bypass for Lower Limb Ischemic Syndrome in Humans Completed NCT02117206 Phase 4 L-arginine (L-arginine Veyron);Nacl
20 Strategy for Managing Antiplatelet Therapy in the Perioperative Period of Non Coronary Surgery Completed NCT00190307 Phase 4 aspirin 75 mg/day
21 Magnetic Resonance Characterization of Carotid Atherosclerotic Plaque in Vivo: Effect of High Density Lipoprotein Elevation on Plaque Morphology Completed NCT00307307 Phase 4 Niacin/simvastatin compared to simvastatin alone at 2 doses
22 Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study) Recruiting NCT02829151 Phase 4 Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) );Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel;Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol
23 Impact of Early CRRT or Beta-blocker Intervention in Patients Receiving VA-ECMO Support on 30-day Mortality: A 2 × 2 Partial Factorial Randomized Controlled Trial Recruiting NCT03549923 Phase 4 Esmolol;Standard care
24 The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery of Femoropopliteal TASC C&D Lesions Active, not recruiting NCT01952457 Phase 4
25 Plaque Removal Versus Open Bypass Surgery For Critical Limb Ischemia Terminated NCT00504088 Phase 4
26 Pregabalin for Pain Reduction in Critical Limb Ischemia - A Double Blind, Randomized Controlled Study Terminated NCT00403780 Phase 4 pregabalin;placebo
27 Balloon Angioplasty vs. Cutting Balloon Angioplasty of Femoropopliteal Arteries- a Randomized Controlled Trial Terminated NCT00437905 Phase 4
28 Cilostazol After Lower Extremity Arterial Revascularization Trial (CLEAR) Terminated NCT02374957 Phase 4 Cilostazol
29 Metformin, Muscle Energetics, and Vascular Function in Older Adults With Peripheral Artery Disease Terminated NCT01901224 Phase 4 Metformin 1000 mg;Placebo
30 Impact of Ticagrelor and Aspirin Versus Clopidogrel and Aspirin in Patients With Claudication and Peripheral Arterial Disease (PAD): Thrombus Burden Assessed by Optical Coherence Tomography Terminated NCT02407314 Phase 4 Aspirin;Aspirin + Ticagrelor
31 Effect of Normalization of Fasting Glucose by Intensified Insulin Therapy on the Incidence of Restenosis After Peripheral Angioplasty in Patients With Type 2 Diabetes. Terminated NCT01150617 Phase 4 Insulin glargine plus insulin analogues
32 A Double-blind, Randomized, Parallel Design Two Center Study to Compare the Effect of Vorapaxar vs. Placebo on Lower Extremity Vein Graft Maturation, Remodeling, and Function Withdrawn NCT02975583 Phase 4 Vorapaxar;Placebos
33 Evaluation of Ranolazine on Skeletal Muscle Endpoints During Exercise In Subjects With Chronic Angina and Peripheral Arterial Disease Withdrawn NCT00657514 Phase 4 Ranolazine;Placebo
34 Proteomics and Stem Cell Therapy as a New Vascularization Strategy Withdrawn NCT02408991 Phase 4 Neupogen
35 Stem Cells In Wound Healing With Collagen Matrix as a Carrier Withdrawn NCT02314416 Phase 4
36 Thalidomide for the Treatment of Malnutrition Inflammation Syndrome in Peritoneal Dialysis Patients: A Randomized Control Trial Withdrawn NCT00390247 Phase 4 thalidomide
37 A Randomized, Controlled Trial of Autologous Platelet Gel Treatment in Diabetic Foot Ulcers Withdrawn NCT00338702 Phase 4
38 Distal Venous Arterialisation in the Treatment of Critical Ischemia of Lower Limb Unknown status NCT01211925 Phase 2, Phase 3 Aspirin
39 Study of Parameters of Infracyanine Angiography as Diagnostic Tool of Critical Limb Ischemia Unknown status NCT02820467 Phase 3
40 Prospektive, Randomisierte Und Kontrollierte Studie Zum Einfluss Des VADOplex-Systems Auf Die Lebensqualität im Rahmen Der Behandlung Der Chronisch-kritischen Extremitätenischämie im Stadium IV Nach Fontaine Unknown status NCT02034539 Phase 2, Phase 3
41 Safety and Effectiveness of the SurgWerksTM-CLI Kit and VXPTM System for the Rapid Intra-operative Aspiration, Preparation and Intramuscular Injection of Concentrated Autologous Bone Marrow Cells Into the Ischemic Index Limb of Rutherford Category 5 Non-Reconstructable Critical Limb Ischemia Patients Unknown status NCT02538978 Phase 3
42 Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia A Double Blind, Placebo Controlled, Study in Diabetic and Non-diabetic Patients Unknown status NCT00539266 Phase 2, Phase 3
43 Security and Effectiveness of Autologous Bone Marrow Stem Cell Transplantation to Avoid Amputations in Patients With Limb-threatening Ischemia: A Multicentric Randomized Placebo-controlled Double-blind Study Unknown status NCT00434616 Phase 2, Phase 3
44 Pilot Study of Treatment of Chronic Critical Limb Ischemia With G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells Completed NCT01833585 Phase 3
45 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Ixmyelocel-T In Subjects With Critical Limb Ischemia And No Options For Revascularization Completed NCT01483898 Phase 3
46 Pivotal Study of the Safety and Effectiveness of Autologous Bone Marrow Aspirate Concentrate (BMAC) for the Treatment of Critical Limb Ischemia Due to Peripheral Arterial Disease Completed NCT01245335 Phase 3
47 A Prospective, Multi-center, Single Arm Study With a Nitinol Self-Expanding Paclitaxel-Eluting Stent in the Treatment of Atherosclerotic Tibial-peroneal Arteries Completed NCT01630070 Phase 2, Phase 3
48 Cell Therapy in Critical Limb Ischemia Completed NCT00904501 Phase 3
49 A Randomized Double-Blind Placebo-Controlled Parallel Group Study of the Efficacy and Safety of XRP0038/NV1FGF on Amputation or Any Death in Critical Limb Ischemia Patients With Skin Lesions Completed NCT00566657 Phase 3
50 A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of CirculaseTM in Conjunction With Peripheral Revascularization for the Treatment of Critical Leg Ischemia Completed NCT00059657 Phase 3 Ecraprost in lipid emulsion

Search NIH Clinical Center for Limb Ischemia

Genetic Tests for Limb Ischemia

Anatomical Context for Limb Ischemia

MalaCards organs/tissues related to Limb Ischemia:

41
Endothelial, Bone, Bone Marrow, Heart, Skeletal Muscle, Kidney, Lung

Publications for Limb Ischemia

Articles related to Limb Ischemia:

(show top 50) (show all 6861)
# Title Authors PMID Year
1
Absent or diminished pedal pulses and estimated GFR decline in patients with diabetic kidney disease. 38
31352861 2019
2
Neuroprotection mediated by remote preconditioning is associated with a decrease in systemic oxidative stress and changes in brain and blood glutamate concentration. 38
31095978 2019
3
Diabetes impairs the angiogenic capacity of human adipose-derived stem cells by reducing the CD271+ subpopulation in adipose tissue. 38
31362891 2019
4
Cannulation strategies in acute type A dissection repair: A systematic axillary artery approach. 38
30770117 2019
5
Use of a temporary shunt to preserve the patency of a hemodialysis graft while performing ipsilateral axillo-femoral bypass. 38
30618343 2019
6
The Role of Venoarterial Extracorporeal Membrane Oxygenation in Postcardiotomy Cardiogenic Shock. 38
31351559 2019
7
Treatment of acute limb ischemia in an Impella CP patient. 38
31104536 2019
8
Endovascular Extra-Anatomic Femoro-Popliteal Bypass for Limb Salvage in Chronic Critical Limb Ischemia. 38
31214761 2019
9
In experimental peripheral arterial disease, type 2 diabetes alters post-ischemic gene expression. 38
31293900 2019
10
Isolation of induced pluripotent stem cell-derived endothelial progenitor cells from sac-like structures. 38
31178142 2019
11
Loss to follow-up 1 year after lower extremity peripheral vascular intervention is associated with worse survival. 38
31195896 2019
12
Clinical Pearls of Venoarterial Extracorporeal Membrane Oxygenation for Cardiogenic Shock. 38
31364329 2019
13
Ipsilateral Antegrade Angioplasty for Flush Superficial Femoral Artery Occlusion versus Open Bypass Surgery. 38
31394228 2019
14
Femoral Balloon-Oriented Puncture for True Lumen Reentry in the Common Femoral Artery After Subintimal Retrograde Recanalization of Superficial Femoral Artery Ostial Occlusion: The FORLEE Technique. 38
31088320 2019
15
Percutaneous Trans-venous Femoropopliteal Bypass in Long Occlusions of the Superficial Femoral Artery. 38
31435757 2019
16
Tao-Hong-Si-Wu decoction reduces ischemia reperfusion rat myoblast cells calcium overloading and inflammation through the Wnt/IP3R/CAMKII pathway. 38
30950126 2019
17
Axillary-bifemoral and axillary-unifemoral artery grafts have similar perioperative outcomes and patency. 38
31395294 2019
18
IN.PACT SFA Clinical Study Using the IN.PACT Admiral Drug-Coated Balloon in a Chinese Patient Population. 38
31204595 2019
19
Prediction of Limb Salvage Following Percutaneous Vascular Intervention Using a Composite Tibial Artery Perfusion Score. 38
31001667 2019
20
Overview of arterial pathology related to repetitive trauma in athletes. 38
31113722 2019
21
Outcome Comparison between Open and Endovascular Management of TASC II D Aortoiliac Occlusive Disease. 38
31394230 2019
22
Clinical outcome of drug-coated balloon angioplasty in patients with femoropopliteal disease: A real-world single-center experience. 38
31401115 2019
23
Catheter-directed intra-arterial thrombolysis for lower extremity arterial occlusions. 38
31375648 2019
24
Impact of Cannula Size on Clinical Outcomes in Peripheral Venoarterial Extracorporeal Membrane Oxygenation. 38
30074498 2019
25
Clinical Experience and Management of Squat-Induced Lower Extremity Arterial Ischemia. 38
31382002 2019
26
Toll-like receptors 2 and 6 mediate apoptosis and inflammation in ischemic skeletal myotubes. 38
31084431 2019
27
Human Endothelial Colony Forming Cells Express Intracellular CD133 that Modulates their Vasculogenic Properties. 38
30879244 2019
28
Acute Limb Ischemia: An Update on Diagnosis and Management. 38
31416204 2019
29
The effect of income and insurance on the likelihood of major leg amputation. 38
30853385 2019
30
Risk stratification for low extremity amputation in critical limb ischemia patients who have undergone endovascular revascularization: A survival tree analysis. 38
31415395 2019
31
Inflammatory Cytokines Associated With Failure of Lower Extremity Endovascular Revascularization (LER): A Prospective Study of a Population With Diabetes. 38
31371431 2019
32
Endovascular-First Treatment Is Associated With Improved Amputation-Free Survival in Patients With Critical Limb Ischemia. 38
31357888 2019
33
Reproducible hindlimb ischemia model based on photochemically induced thrombosis to evaluate angiogenic effects. 38
31433972 2019
34
Acute kidney injury in patients undergoing endovascular therapy for critical limb ischemia. 38
31419029 2019
35
Umbilical Cord-Derived Mesenchymal Stem Cells Relieve Hind limb Ischemia by Promoting Angiogenesis in Mice. 38
31407635 2019
36
Perfusion Assessment in Critical Limb Ischemia: Principles for Understanding and the Development of Evidence and Evaluation of Devices: A Scientific Statement From the American Heart Association. 38
31401843 2019
37
Cost-effectiveness of the treatments for critical limb ischemia in the elderly population. 38
30922757 2019
38
Delayed Fasciotomy Is Associated with Higher Risk of Major Amputation in Patients with Acute Limb Ischemia. 38
31034949 2019
39
Does the new vascular management of acute limb ischemia have effective results with lower treatment costs. 38
31223014 2019
40
HMGB1/RAGE pro-inflammatory axis promotes vascular endothelial cell apoptosis in limb ischemia/reperfusion injury. 38
31136947 2019
41
Impact of low activity of daily living on the prognosis of patients with critical limb ischemia and sarcopenia. 38
31394242 2019
42
Exhaustion of the bone marrow progenitor cell reserve is associated with major events in severe limb ischemia. 38
30929097 2019
43
Dexmedetomidine protects against lung injury induced by limb ischemia-reperfusion via the TLR4/MyD88/NF-κB pathway. 38
31373750 2019
44
Cell-mediated delivery of VEGF modified mRNA enhances blood vessel regeneration and ameliorates murine critical limb ischemia. 38
31425721 2019
45
Safety and Efficacy of Placenta-Derived Mesenchymal Stem Cell Treatment for Diabetic Patients with Critical Limb Ischemia: A Pilot Study. 38
31412379 2019
46
In vivo efficacy of endothelial growth medium stimulated mesenchymal stem cells derived from patients with critical limb ischemia. 38
31399109 2019
47
External validation of CLI Frailty Index and assessment of predictive value of modified CLI Frailty Index for patients with critical limb ischemia undergoing infrainguinal revascularization. 38
30890090 2019
48
Coexistence of proangiogenic potential and increased MMP-9, TIMP-1, and TIMP-2 levels in the plasma of patients with critical limb ischemia. 38
31273966 2019
49
Experimental supporting data on evaluation of skeletal muscle perfusion in canine hind limb ischemia model using color-coded digital subtraction angiography. 38
31304204 2019
50
Demystifying the Use of Self-Expandable Interwoven Nitinol Stents in Femoropopliteal Peripheral Arterial Disease. 38
31009734 2019

Variations for Limb Ischemia

Expression for Limb Ischemia

Search GEO for disease gene expression data for Limb Ischemia.

Pathways for Limb Ischemia

Pathways related to Limb Ischemia according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.19 VWF VEGFA TNF TEK PLAT PGF
2
Show member pathways
14.04 VWF VEGFA TNF TEK NOS3 IL6
3
Show member pathways
13.88 VEGFA TNF TEK PGF KDR IL6
4
Show member pathways
13.74 VEGFA TEK PGF NOS3 KDR IL6
5
Show member pathways
13.69 TNF TEK NOS3 KDR IL6 HGF
6
Show member pathways
13.58 TEK PGF NOS3 KDR IL6 HGF
7
Show member pathways
13.57 VEGFA TNF TEK PGF KDR IL6
8
Show member pathways
13.5 VWF VEGFA TNF TEK KDR HGF
9
Show member pathways
13.41 VWF VEGFA TNF TEK IL6 HIF1A
10
Show member pathways
13.41 TNF TEK PGF NOS3 KDR IL6
11
Show member pathways
13.35 TEK PGF KDR IL6 HGF FGF2
12
Show member pathways
13.34 VWF VEGFA TEK SELE PLAT NOS3
13
Show member pathways
13.33 TNF TEK PGF KDR IL6 HGF
14
Show member pathways
13.27 VEGFA TNF TEK PGF NOS3 KDR
15
Show member pathways
13.09 PGF KDR IL6 HGF FGF2 CXCL12
16
Show member pathways
13.05 PGF KDR IL6 HIF1A HGF FGF2
17
Show member pathways
13.01 VEGFA TNF IL6 HIF1A FGF2 CXCL12
18
Show member pathways
12.99 VEGFA TNF SELE KDR IL6 CCL2
19
Show member pathways
12.94 VWF VEGFA TNF TEK PGF NOS3
20
Show member pathways
12.9 VWF VEGFA PGF KDR HGF
21 12.89 VEGFA PGF IL6 HIF1A HGF FGF2
22 12.81 VEGFA TNF TEK PGF KDR HGF
23
Show member pathways
12.79 VEGFA TEK PGF KDR HGF FGF2
24
Show member pathways
12.75 TNF PGF KDR IL6 HGF FGF2
25
Show member pathways
12.72 VEGFA KDR IL6 HGF FGF2
26
Show member pathways
12.69 VEGFA NOS3 KDR CXCL12 CCL2
27
Show member pathways
12.66 TNF TEK NOS3 IL6 FGF2 CCL2
28
Show member pathways
12.46 VEGFA SELE NOS3 KDR CCL2
29
Show member pathways
12.45 TEK PGF KDR IL6 HGF FGF2
30
Show member pathways
12.41 VEGFA PGF NOS3 KDR
31
Show member pathways
12.37 TNF PLAT IL6 CCL2
32 12.34 VEGFA TNF KDR HIF1A HGF FGF2
33
Show member pathways
12.29 TNF PGF KDR IL6 HGF FGF2
34
Show member pathways
12.27 VEGFA NOS3 KDR FGF2
35 12.21 VEGFA TNF IL6 HIF1A
36 12.14 VEGFA KDR IL6 HGF FGF2
37
Show member pathways
12.1 PGF KDR IL6 HGF FGF2 CXCL12
38 12.04 TNF SELE IL6 EDN1 CCL2
39 11.99 VEGFA TEK NOS3 IL6 HIF1A EDN1
40
Show member pathways
11.96 TNF NOS3 IL6
41
Show member pathways
11.94 VEGFA PGF NOS3 KDR HIF1A
42 11.92 VEGFA TNF IL6 HIF1A HGF FGF2
43 11.9 VEGFA TNF TEK IL6 CXCL12 CCL2
44 11.9 VEGFA TNF SELE PLAT NOS3 KDR
45 11.8 VEGFA TNF SELE NOS3 IL6 EDN1
46 11.78 VEGFA HIF1A EDN1 CXCL12
47 11.77 PGF IL6 HGF FGF2 CXCL12
48 11.76 TNF IL6 CCL2
49
Show member pathways
11.76 VEGFA TNF SELE IL6
50 11.72 VEGFA PLAT FGF2

GO Terms for Limb Ischemia

Cellular components related to Limb Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 VEGFA TNF SELE PLAT PGF IL6
2 membrane raft GO:0045121 9.62 TNF TEK SELE KDR
3 extracellular region GO:0005576 9.47 VWF VEGFA TNF TEK PLAT PGF
4 platelet alpha granule lumen GO:0031093 9.43 VWF VEGFA HGF
5 Weibel-Palade body GO:0033093 9.16 VWF EDN1

Biological processes related to Limb Ischemia according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.99 TNF TEK KDR FGF2 CCL2
2 positive regulation of cell migration GO:0030335 9.97 VEGFA KDR HGF EDN1 CXCL12
3 positive regulation of protein kinase B signaling GO:0051897 9.96 TNF TEK HGF FGF2
4 MAPK cascade GO:0000165 9.96 TNF TEK HGF FGF2 CCL2
5 negative regulation of gene expression GO:0010629 9.91 VEGFA TNF KDR HIF1A EDN1 ACE
6 cytokine-mediated signaling pathway GO:0019221 9.91 VEGFA TNF IL6 HIF1A HGF FGF2
7 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.9 VEGFA IL6 HGF
8 cell chemotaxis GO:0060326 9.89 HGF CXCL12 CCL2
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.89 VEGFA TNF IL6
10 cellular response to interleukin-1 GO:0071347 9.89 HIF1A EDN1 CCL2
11 regulation of blood pressure GO:0008217 9.88 NOS3 EDN1 ACE
12 positive regulation of protein phosphorylation GO:0001934 9.88 VEGFA TNF TEK PGF KDR HGF
13 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.87 VEGFA PGF KDR
14 humoral immune response GO:0006959 9.87 TNF IL6 CCL2
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.87 TNF IL6 EDN1
16 positive regulation of cell adhesion GO:0045785 9.85 VEGFA TNF CXCL12
17 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.84 TNF FGF2 EDN1
18 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.84 TNF TEK KDR HGF
19 positive regulation of cell division GO:0051781 9.83 VEGFA PGF FGF2
20 animal organ regeneration GO:0031100 9.82 PGF HGF CXCL12
21 protein kinase B signaling GO:0043491 9.81 TNF KDR CCL2
22 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.81 VEGFA KDR FGF2
23 positive regulation of MAP kinase activity GO:0043406 9.81 VEGFA TNF FGF2 EDN1
24 lipopolysaccharide-mediated signaling pathway GO:0031663 9.8 TNF NOS3 CCL2
25 response to hypoxia GO:0001666 9.8 VEGFA TEK PLAT PGF HIF1A EDN1
26 sprouting angiogenesis GO:0002040 9.79 VEGFA TEK PGF
27 positive regulation of endothelial cell migration GO:0010595 9.78 VEGFA TEK KDR EDN1
28 positive regulation of focal adhesion assembly GO:0051894 9.77 VEGFA TEK KDR
29 cell migration involved in sprouting angiogenesis GO:0002042 9.76 VEGFA KDR FGF2
30 positive chemotaxis GO:0050918 9.76 VEGFA PGF HGF FGF2
31 angiogenesis GO:0001525 9.76 VEGFA TEK PGF NOS3 KDR HIF1A
32 positive regulation of chemokine production GO:0032722 9.74 TNF IL6 HIF1A
33 positive regulation of DNA biosynthetic process GO:2000573 9.73 HGF FGF2
34 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.72 KDR CCL2
35 positive regulation of positive chemotaxis GO:0050927 9.72 VEGFA KDR
36 vascular endothelial growth factor signaling pathway GO:0038084 9.72 VEGFA PGF KDR
37 positive regulation of blood vessel endothelial cell migration GO:0043536 9.72 VEGFA NOS3 KDR HIF1A FGF2
38 negative regulation of lipid storage GO:0010888 9.71 TNF IL6
39 neutrophil mediated immunity GO:0002446 9.71 IL6 ACE
40 positive regulation of receptor biosynthetic process GO:0010870 9.7 HIF1A EDN1
41 positive regulation of axon extension involved in axon guidance GO:0048842 9.7 VEGFA CXCL12
42 induction of positive chemotaxis GO:0050930 9.7 VEGFA PGF CXCL12
43 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.69 NOS3 EDN1
44 positive regulation of neuroinflammatory response GO:0150078 9.68 TNF IL6
45 positive regulation of mast cell chemotaxis GO:0060754 9.68 VEGFA PGF
46 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.67 VEGFA HIF1A
47 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.67 VEGFA KDR
48 peptidyl-tyrosine phosphorylation GO:0018108 9.67 TEK KDR
49 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.64 VEGFA ACE
50 regulation of endothelial cell apoptotic process GO:2000351 9.63 TNF TEK

Molecular functions related to Limb Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integrin binding GO:0005178 9.56 VWF KDR FGF2 CXCL12
2 chemoattractant activity GO:0042056 9.46 VEGFA PGF HGF FGF2
3 growth factor activity GO:0008083 9.43 VEGFA PGF IL6 HGF FGF2 CXCL12
4 protein tyrosine kinase activity GO:0004713 9.37 TEK KDR
5 cytokine activity GO:0005125 9.17 VEGFA TNF IL6 FGF2 EDN1 CXCL12
6 protein binding GO:0005515 10.22 VWF VEGFA TNF TEK SELE PLAT

Sources for Limb Ischemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....